VANCOUVER, Canada — September 11, 2026
Clearmind Medicine Inc. announced that the first patients with Alcohol Use Disorder (AUD) have been enrolled in its ongoing clinical trial evaluating CMND-100, marking the first time the company’s investigational psychedelic-derived treatment has been administered to patients with AUD. The first two participants were enrolled at Hadassah Medical Center in Jerusalem, Israel, advancing CMND-100 from evaluation in healthy participants into a targeted patient population. Clearmind is developing CMND-100 as a non-hallucinogenic neuroplastogen designed to address neuropsychiatric, metabolic and addiction disorders. The clinical milestone represents an important transition for the program as the company begins generating patient-specific safety, pharmacokinetic and preliminary efficacy data in AUD. Clearmind said the enrollment progress strengthens the development trajectory for CMND-100 and moves the company closer to key clinical milestones for its lead candidate.
CMND-100 Enters Patient-Based Clinical Evaluation
The ongoing clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in people with Alcohol Use Disorder. Before entering the AUD population, Clearmind had evaluated CMND-100 at multiple dose levels in healthy participants as part of its broader clinical development program. The transition into patients represents a significant development step because it allows the company to assess the candidate under the clinical conditions relevant to its intended indication. The study will generate data across several key parameters, including how CMND-100 is tolerated, how the compound behaves in the body and whether preliminary signals of therapeutic activity can be observed. Patient enrollment at Hadassah Medical Center provides the first clinical testing of CMND-100 specifically for AUD, creating an important foundation for subsequent development decisions. The company has not yet reported efficacy results from the newly enrolled patients, making future clinical readouts critical for determining the candidate’s potential.
Non-Hallucinogenic Neuroplastogen Targets Addiction
Clearmind is pursuing a differentiated approach to addiction treatment through psychedelic-derived compounds designed without hallucinogenic effects. The company describes CMND-100 as a proprietary psychedelic-based, non-hallucinogenic neuroplastogen, reflecting its strategy to retain potentially useful neuroplasticity-related properties while developing a medicine intended for scalable clinical use. Alcohol Use Disorder remains a significant and underserved health problem, creating an opportunity for new pharmacological approaches that could expand treatment options. Clearmind’s broader research strategy focuses on developing second-generation neuroplastogen-derived therapeutics for neuropsychiatric, metabolic and addiction disorders. The company aims to develop psychedelic-based compounds for potential commercialization as regulated medicines, foods or supplements, depending on the applicable development pathway. For CMND-100, the AUD clinical trial represents the next step in testing whether the company’s scientific approach can produce a clinically meaningful treatment candidate.
Advertisement
Clearmind Builds Intellectual Property and Clinical Pipeline
The CMND-100 clinical program is supported by Clearmind’s broader intellectual-property strategy and focus on developing proprietary neuroplastogen medicines. The company currently reports an intellectual-property portfolio comprising 19 patent families and 32 granted patents, with plans to pursue additional protection for its compounds where appropriate. Clearmind also intends to remain opportunistic in acquiring additional intellectual property to strengthen its development portfolio. The company’s immediate priority is advancing CMND-100 through the AUD trial and generating the clinical evidence needed to determine its future development path. Successful progression could establish CMND-100 as a lead program within Clearmind’s addiction-focused pipeline while providing proof of concept for its non-hallucinogenic neuroplastogen strategy. With the first AUD patients now enrolled and treated, Clearmind has moved CMND-100 into a clinically relevant stage of development, setting up future safety, pharmacokinetic and preliminary efficacy milestones that will shape the program’s next phase.
Source: Clearmind Medicine press release
